Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Anna Suvorova received her master's degree in 2018 from the Bauman Moscow Technical University and is currently a graduate student at the Faculty of Biotechnical Technologies of this university.
Approach to combine drugs with erythrocytes is performed by means of forming transient pores in the erythrocyte membrane, thus allowing for the drug to enter the erythrocyte. In the process of dialysis, low molecular weight metabolites that are absent in a hypotonic solution can come out of the erythrocyte. The goal of drug development is to apply our technology into clinical practice. It requires a large-scale production of drug carries. Today there are 2 analogues of the device. ERYTECH Pharma based in Lyon (France) developed a therapeutic solution GRASPA for the treatment of acute lymphoblastic leukemia: positive results were obtained in children and adults as well as in elderly patients. Patients administered with homologous erythrocytes loaded with L-asparaginase GRASPA showed a reduction in the number and the severity of allergic reactions as compared to the free enzyme. EryDel, in Italy, has developed EryDex, a system to deliver dexamethasone at stable low systemic levels over an extended period of time. The biotechnical system for the detection of asparaginase in human erythrocytes includes a number of occurrences (?????????).